Johnson & Johnson (NYSE:JNJ) Position Boosted by Sumitomo Mitsui DS Asset Management Company Ltd

Sumitomo Mitsui DS Asset Management Company Ltd increased its holdings in Johnson & Johnson (NYSE:JNJ) by 3.6% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 483,774 shares of the company’s stock after buying an additional 16,751 shares during the quarter. Johnson & Johnson comprises 0.8% of Sumitomo Mitsui DS Asset Management Company Ltd’s portfolio, making the stock its 27th largest holding. Sumitomo Mitsui DS Asset Management Company Ltd’s holdings in Johnson & Johnson were worth $70,708,000 as of its most recent SEC filing.

Other institutional investors have also recently added to or reduced their stakes in the company. Vestmark Advisory Solutions Inc. lifted its position in Johnson & Johnson by 12.7% in the fourth quarter. Vestmark Advisory Solutions Inc. now owns 19,587 shares of the company’s stock worth $3,070,000 after purchasing an additional 2,201 shares during the period. Meridian Financial Partners LLC acquired a new stake in shares of Johnson & Johnson during the 2nd quarter valued at $1,626,000. Summit Financial Wealth Advisors LLC lifted its position in shares of Johnson & Johnson by 26.3% during the 1st quarter. Summit Financial Wealth Advisors LLC now owns 5,392 shares of the company’s stock valued at $853,000 after acquiring an additional 1,122 shares during the last quarter. Gilbert & Cook Inc. lifted its position in shares of Johnson & Johnson by 3.3% during the 4th quarter. Gilbert & Cook Inc. now owns 9,111 shares of the company’s stock valued at $1,428,000 after acquiring an additional 288 shares during the last quarter. Finally, Private Wealth Partners LLC lifted its position in shares of Johnson & Johnson by 8.7% during the 4th quarter. Private Wealth Partners LLC now owns 74,330 shares of the company’s stock valued at $11,650,000 after acquiring an additional 5,930 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Trading Up 1.0 %

NYSE JNJ opened at $165.86 on Friday. Johnson & Johnson has a 1-year low of $143.13 and a 1-year high of $165.98. The company has a current ratio of 1.07, a quick ratio of 0.85 and a debt-to-equity ratio of 0.44. The company has a market capitalization of $399.17 billion, a PE ratio of 10.34, a price-to-earnings-growth ratio of 2.63 and a beta of 0.52. The firm’s fifty day simple moving average is $155.68 and its 200-day simple moving average is $153.51.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Wednesday, July 17th. The company reported $2.82 earnings per share for the quarter, topping analysts’ consensus estimates of $2.71 by $0.11. Johnson & Johnson had a net margin of 46.34% and a return on equity of 36.60%. The business had revenue of $22.45 billion for the quarter, compared to the consensus estimate of $22.33 billion. During the same period in the prior year, the business posted $2.80 earnings per share. Johnson & Johnson’s revenue for the quarter was up 4.3% compared to the same quarter last year. As a group, sell-side analysts anticipate that Johnson & Johnson will post 10.07 earnings per share for the current fiscal year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 10th. Shareholders of record on Tuesday, August 27th will be given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 2.99%. The ex-dividend date of this dividend is Tuesday, August 27th. Johnson & Johnson’s payout ratio is 30.92%.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on JNJ. Sanford C. Bernstein increased their price objective on Johnson & Johnson from $161.00 to $171.00 in a research report on Thursday, July 18th. StockNews.com upgraded Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Friday, August 16th. The Goldman Sachs Group cut their price objective on Johnson & Johnson from $160.00 to $155.00 and set a “neutral” rating for the company in a research report on Friday, July 19th. Royal Bank of Canada reiterated an “outperform” rating and set a $175.00 price objective on shares of Johnson & Johnson in a research report on Tuesday, July 30th. Finally, Daiwa Capital Markets downgraded shares of Johnson & Johnson from an “outperform” rating to a “neutral” rating and cut their target price for the company from $160.00 to $150.00 in a research note on Tuesday, July 23rd. Seven analysts have rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus price target of $173.21.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.